WEST PALM BEACH, FL and WASHINGTON, DC--(Marketwire - July 24, 2012) -
TNI BioTech, Inc. (PINKSHEETS: TNIB
) took a major step forward in signing a Memorandum of Agreement with GB Oncology and Imaging Group LTD. ("GB") to equip and operate oncology and infectious diseases clinics in Equatorial Guinea.
The companies believe this is an important step as cancer is now one of the leading causes of death in developing countries and there are more deaths in the world from cancer than from HIV/AIDS, tuberculosis, and malaria combined. The goal of the partnership, with assistance from the government of Equatorial Guinea, is to provide better access and public awareness for the prevention, diagnoses and treatment of cancer and other infectious diseases.
The clinic will be located in the capital city of Malabo, and will serve as the hub for several other general health care clinics throughout Equatorial Guinea and the surrounding countries. The clinic will provide treatments for cancer and other infectious diseases. TNIB will deliver advanced treatments -- including safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives. At the same time, TNI BioTech will support the patient with its patented therapies to boost the immune system and improve the quality of life.
Dr. Herndon said, "This partnership is the first step in many that will allow TNIB and GB to begin to deliver quality care not only to the people of Equatorial Guinea but hopefully throughout Africa. The need for quality care is critical because today advanced cancer treatment is available in only 23 of Africa's 53 countries, reaching less than 5% of the (total African) population."
About GB Oncology & Imaging Group LTD.
GB Oncology and Imaging Group LTD., a subsidiary of GB Energie LLC, is a Washington D.C.-based minority woman-owned business managed by Dr. Gloria B. Herndon. Dr. Herndon is committed to sourcing sustainable solutions in the field of health care in Africa, and has been involved since the mid 1900s on health-care related issues in Africa and on occasion, she is a consulting resource for the National Institutes of Health (NIH) regarding the impact of the HIV/AIDS pandemic on the insurance industry and provides other AIDS-related information when requested by the United States Department of State.
About TNI BioTech, Inc.
TNI BioTech, Inc. is a biotechnology company researching new treatments and methods for treatment of cancer, HIV/AIDS, and certain autoimmune and other infectious diseases. The primary cytokine, among many others currently being studied by TNIB, is methionine enkephalin ("MENK"). MENK, in both non-human studies and human clinical trials, has been shown to stimulate the immune system.
However, even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK as a valuable candidate in the treatment of the following:
- Autoimmune states such as rheumatoid arthritis and multiple sclerosis;
- As an adjunct to antibiotics in the treatment of infectious diseases;
- In patients undergoing chemotherapy, radiation treatments or surgery; and
- In wound healing, herpes viral infections, and in treatment for the elderly.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service, are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.
See www.tnibiotech.com for more information.